RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost impact of complications in meningococcal disease Evidence from a United States managed care population
Davis, K., Misurski, D., Miller, J., & Karve, S. (2011). Cost impact of complications in meningococcal disease Evidence from a United States managed care population. Human Vaccines, 7(4), 458-465. http://www.landesbioscience.com/journals/vaccines/article/14434/
Objectives: To compare health care utilization and associated costs among patients with and without invasive meningococcal disease (IMD)-related sequelae. Results: We identified 173 patients; 41% had at least one diagnosis claim for IMD-related sequelae. Significantly higher predicted total health care costs were shown for complicated-IMD cases (mean: $72,101), compared with uncomplicated cases (mean: $41,883; p < 0.001). Methods: A retrospective analysis of an administrative claims database from 1998-2009 was performed. Patients with an IMD-related inpatient admission and continuous health plan enrollment were selected and categorized by presence (complicated-IMD) or absence (uncomplicated-IMD) of IMD-related sequelae during the follow-up year. Differences in the follow-up year healthcare utilization and costs between the two groups were tested using univariate and multivariable analyses. Conclusions: We observed significantly higher health care costs among complicated-IMD cases, compared with uncomplicated cases. The substantially higher costs observed among patients with IMD-related sequelae warrant inclusion of these costs in studies conducting economic evaluations of meningococcal vaccination programs